Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-07-23Clinical Trial Update: A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma [Phase 3]
A Phase 3 clinical trial studying the combination of ibrutinib and rituximab in untreated marginal zone lymphoma is currently active and not…
-
CLINICAL_TRIALS trial_result · 2025-07-10Clinical Trial Update: Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. [Phase 3]
A phase 3 trial comparing lenalidomide plus rituximab followed by lenalidomide versus rituximab maintenance in relapsed/refractory follicula…
-
CLINICAL_TRIALS trial_result · 2025-07-08Clinical Trial Update: Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)
This clinical trial update summarizes completed results from a surveillance study of Revlimid (lenalidomide) in relapsed or refractory folli…
-
CLINICAL_TRIALS trial_result · 2025-07-02Clinical Trial Update: A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma [Phase 2]
This clinical trial update describes a Phase II study evaluating rituximab plus venetoclax as frontline therapy for marginal zone lymphoma, …
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: Combating Cancer-Related Fatigue: A Personalized Supportive Care Program [NA]
This clinical trial update reports a UNC Lineberger Comprehensive Cancer Center study recruiting participants for a personalized supportive …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update on a Phase 1/2 study of lenalidomide in combination with obinutuzumab for relapsed indolent non-Hodgkin lymphoma, incl…
-
CLINICAL_TRIALS trial_result · 2025-06-18Clinical Trial Update: A Phase 1 Study of ADI-001 in B Cell Malignancies [Phase 1]
The Phase 1 study of ADI-001 in B cell malignancies has been terminated.
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial [Phase 2]
A randomized Phase II trial evaluating orelabrutinib plus rituximab versus R-CVP in untreated marginal zone lymphoma (MZL). The study is cur…
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating orelabrutinib in combination with rituximab as first-line systemic therapy for marginal zone lymphoma…
-
CLINICAL_TRIALS research · 2025-06-06Clinical Trial Update: BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma [Phase 2]
Clinical trial update for a Phase 2 study evaluating BR combined with OR in treatment-naïve marginal zone lymphoma; recruitment status is NO…
-
CLINICAL_TRIALS research · 2025-05-22Clinical Trial Update: Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL [Phase 2]
A Phase 2 trial is exploring orelabrutinib combined with zuberitamab as initial therapy for marginal zone lymphoma and is currently recruiti…
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating dendritic cell therapy with cryosurgery and pembrolizumab in various Non-Hodgkin lymphoma subtypes, w…
-
CLINICAL_TRIALS trial_result · 2025-05-14Clinical Trial Update: Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A phase 1/2 trial evaluated a conditioning regimen incorporating venetoclax, carmustine, etoposide, cytarabine, and melphalan before stem ce…
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]
Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
Clinical trial update on a Phase I/II study evaluating the safety of autologous CD20 CAR-T cells in relapsed or refractory B-cell non-Hodgki…
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating mosunetuzumab with or without polatuzumab vedotin and obinutuzumab for untreated indolent B-cell non-Hod…
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma [Phase 2]
Phase 2 trial of HMPL-689 for relapsed/refractory marginal zone lymphoma and follicular lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. [Phase 3]
Phase 3 trial evaluating tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in relapsed/refractory f…
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: Obinutuzumab in Marginal Zone Lymphoma [Phase 2]
This update reports an ongoing Phase 2 clinical trial of obinutuzumab for marginal zone lymphoma, currently active and not recruiting.
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients [Phase 2]
Phase 2 trial update indicates a study of copanlisib in combination with rituximab for marginal zone lymphoma is currently active but not re…
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies [Phase 1]
Phase 1 clinical trial update for BP1002 in advanced lymphoid malignancies across several B-cell and T-cell lymphomas; trial status is activ…
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies [Phase 1, Phase 2]
This completed Phase 1/2 trial evaluates the combination of cirmtuzumab and ibrutinib in patients with B-cell lymphoid malignancies, includi…
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)
This clinical trial update describes a study to evaluate the effectiveness and safety of zanubrutinib in Italian patients with marginal zone…
-
CLINICAL_TRIALS trial_result · 2025-02-04Clinical Trial Update: Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies [Phase 1]
Phase 1 VENOM trial evaluating venetoclax with obinutuzumab and magrolimab in relapsed and refractory indolent B-cell malignancies has compl…
-
CLINICAL_TRIALS research · 2025-02-04Clinical Trial Update: Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas
A clinical trial in Italy is evaluating clinical characteristics and outcomes in patients with Marginal Zone Lymphoma. The study is currentl…